China Pharmaceutical: Pfizer’s new crown drug PAXLOVID-related business is expected to account for a small proportion of the company’s overall business volume – yqqlm

　　Chinese medicineMarch 14 eveningannouncementthe company on March 9, 2022PfizerThe company signed an agreement and will be responsible for the period of the agreement (2022)PfizerCommercial operation of the company’s new coronavirus treatment drug PAXLOVID in the Chinese mainland market.The product is a prescription drug and has not yet entered the national medical insurance and domestic new coronary pneumonia diagnosis and treatment programs. The final use and sales are affected by factors such as epidemic prevention and control, and there are great uncertainties. , for the company’s recent operationsperformanceNo major impact.

(Article source: Interface News)

Article source: Interface News

Responsible editor: 3

Original title: Chinese medicine: Pfizer’s new crown drug PAXLOVID-related business is expected to account for a small proportion of the company’s overall business volume